1. Introduction

Commercial Biosurveillance Accountability Doctrine and Governance refers to the legal principles, regulatory mechanisms, and institutional responsibilities governing private-sector collection, analysis, sharing, and commercialization of biological and health-related information for surveillance purposes.

The term is best understood as an analytical legal framework, rather than the name of a single, universally recognized doctrine established by a court. It draws on established areas of law, including privacy, data protection, medical confidentiality, consumer protection, employment discrimination, biotechnology regulation, and corporate accountability.

Commercial biosurveillance may involve pharmaceutical companies, health insurers, genetic-testing services, hospitals, employers, wearable-device companies, biotechnology firms, and data analytics providers.

Examples include:

A genetic-testing company selling or sharing genetic data with a pharmaceutical research partner.

A health insurer using biological indicators or predictive health analytics to assess risk.

An employer purchasing biometric-monitoring services to evaluate employees' health or performance.

A technology company combining wearable-device measurements with location, purchasing, or behavioral data.

A commercial laboratory using biological samples for research beyond the purpose for which they were originally collected.

The central legal question is:

Under what conditions may a commercial entity monitor, analyze, monetize, or transfer biological information, and who is legally accountable when that activity violates individual rights or causes harm?

The answer depends on the jurisdiction, the type of data, the purpose of processing, the consent obtained, and the relationship between the affected person and the organization.

2. Meaning and scope of the doctrine

The proposed framework has five principal elements.

1. Legality and legitimate purpose

Commercial surveillance must have a valid legal basis, a sufficiently defined purpose, and any required regulatory authorization.

2. Informed consent and individual autonomy

Organizations should disclose what is collected, why it is processed, whether it will be shared, and whether it will be used commercially. Consent must satisfy the applicable law.

3. Data security and confidentiality

Companies must apply appropriate safeguards against unauthorized access, disclosure, re-identification, misuse, and data breaches.

4. Accountability and remedies

Responsibility may arise from unlawful processing, misleading representations, negligence, discrimination, breach of confidence, or failure to comply with statutory obligations.

5. Governance and independent oversight

Boards, compliance officers, regulators, courts, and independent auditors should ensure that surveillance practices remain lawful, proportionate, secure, and reviewable.

These elements operate together. Consent alone, for example, does not necessarily make an otherwise prohibited or discriminatory practice lawful.

3. Legal foundations in India

For an Indian-law analysis, the framework must be examined through constitutional privacy, data-protection legislation, medical confidentiality, consumer law, and sector-specific regulation.

A. Constitutional right to privacy

The foundational authority is Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), decided by a nine-judge bench of the Supreme Court of India. The Court recognized privacy as a fundamental right protected by Article 21 and the freedoms in Part III of the Constitution.

Indian Kanoon+1

Its significance for commercial biosurveillance is substantial:

Informational privacy: Biological and health-related information can reveal intimate details about a person's life.

Individual autonomy: People have a strong interest in decisions about the collection and use of personal information.

Legitimate purpose: Intrusive data practices require a defensible legal basis and cannot be justified simply because technology makes them possible.

Proportionality: The nature and extent of an intrusion must be assessed against its legitimate objective, using the applicable constitutional standards.

An important distinction is that Puttaswamy was a constitutional privacy judgment, not a ruling directly imposing every constitutional obligation on private corporations. Claims against private companies must be grounded in applicable statutes, contractual duties, tort principles, or other enforceable legal obligations. Constitutional rights and values can nevertheless shape how legislation and private conduct are interpreted.

B. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 (DPDP Act), together with the Digital Personal Data Protection Rules, 2025, is central to the modern Indian analysis of digital biosurveillance.

The Rules were notified in November 2025 and provide for phased implementation. Not all substantive requirements became operative on the date of notification.

MeitY+2

Key implications include:

Notice and consent: Where consent is the applicable legal basis, organizations must explain the data being processed and the specified purposes in clear language.

Purpose limitation: Companies should not assume that permission to provide a diagnostic service automatically authorizes unrelated advertising, profiling, or commercial disclosure.

Security: Data fiduciaries must implement the safeguards required by the applicable provisions and Rules.

Individual rights: The Act provides rights and grievance mechanisms, subject to its terms and applicable exceptions.

Enhanced oversight: Significant Data Fiduciaries face additional requirements, including impact assessments and audits under the relevant provisions and Rules.

The official Rules address clear notices, breach notification, security safeguards, and additional obligations for Significant Data Fiduciaries.

MeitY+1

Important qualification: The DPDP Act does not create a separate statutory category called “commercial biosurveillance.” Its application depends on whether the information and processing fall within the Act's scope and on the relevant commencement provisions, exceptions, and other applicable laws.

C. Information Technology Act and medical confidentiality

Depending on the circumstances, the Information Technology Act, 2000, its applicable rules, professional confidentiality requirements, and other sectoral laws may also be relevant.

For example, a diagnostic laboratory may face different obligations when it:

Collects a sample to diagnose a disease.

Retains the sample for quality control.

Uses the sample for a new research project.

Transfers genetic information to an overseas commercial partner.

Discloses identifiable results to an employer or insurer.

Each activity requires its own legal analysis. The lawfulness of the initial collection does not automatically settle the lawfulness of every subsequent use.

D. Consumer protection and contractual liability

The Consumer Protection Act, 2019, and ordinary principles of contract law may become relevant where a commercial provider makes misleading privacy promises, supplies a defective service, conceals material facts, or breaches applicable contractual obligations.

Potential consequences depend on the facts and the statutory requirements. They may include consumer complaints, compensation where legally available, regulatory action, contractual remedies, or other relief.

4. Important case laws and their relevance

The following decisions provide useful judicial foundations. Some directly concern genetic privacy, while others establish broader principles applicable by analogy. They should not all be described as precedents specifically deciding commercial biosurveillance.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Facts and issue: The case concerned whether privacy is constitutionally protected as a fundamental right.

Decision: The nine-judge bench unanimously recognized the constitutional right to privacy.

Indian Kanoon+1

Relevance to commercial biosurveillance: The judgment provides a constitutional foundation for protecting personal autonomy and informational privacy. It supports careful scrutiny of systems that collect biological data, construct health profiles, or expose individuals to intrusive monitoring.

Example: If a company builds health-risk profiles from identifiable genetic and biometric information, privacy principles are relevant to evaluating the applicable legal restrictions and safeguards.

Limitation: The judgment does not itself establish a universal prohibition on commercial health-data processing or automatically confer a damages claim against every private company.

Case 2: S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Applications Nos. 30562/04 and 30566/04 · Grand Chamber

Facts: The applicants challenged the retention of their fingerprints, cellular samples, and DNA profiles after criminal proceedings had ended without convictions.

Decision: The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights. It considered the blanket and indefinite retention regime disproportionate. The Court emphasized the sensitive nature of genetic material and the need for safeguards and proportionate retention.

Bailii+1

Relevance to commercial biosurveillance:

Biological samples can reveal considerably more than the immediate information needed for a particular purpose.

Retention itself can raise privacy concerns, even if no immediate injury is demonstrated.

Indefinite retention and unrestricted secondary use require particular scrutiny.

Purpose-specific retention periods and deletion procedures are important governance controls.

Limitation: This was a human-rights case concerning government retention, not a direct judgment against a commercial biotechnology company. Its principles are persuasive analytical guidance, not automatically binding commercial rules in India.

Case 3: District Registrar and Collector, Hyderabad v. Canara Bank (2005)

Supreme Court of India · (2005) 1 SCC 496

Legal principle: The decision examined privacy and confidentiality concerns associated with state access to private financial records.

Relevance: Although the case did not concern genetic databases, it illustrates why confidential records cannot be treated as freely accessible merely because an institution holds them. Similar reasoning is relevant when evaluating access to medical records, laboratory results, and commercially held health information.

For biosurveillance governance, it supports asking whether access is authorized, legally justified, appropriately limited, and subject to safeguards.

Case 4: Norman-Bloodsaw v. Lawrence Berkeley Laboratory (1998)

135 F.3d 1260 · United States Court of Appeals for the Ninth Circuit

Facts: Employees challenged workplace medical testing involving sensitive information, including testing for sickle-cell trait and other conditions, allegedly conducted without their informed knowledge or consent.

Legal significance: The litigation addressed constitutional privacy interests and workplace testing. The court recognized privacy concerns relating to highly personal medical information in the employment setting.

Relevance: Commercial biosurveillance can become especially problematic when employees have little practical ability to refuse monitoring because of economic dependence or workplace power imbalances.

A corporate compliance program should therefore distinguish between a genuinely voluntary health program and monitoring tied to employment decisions.

Limitation: The decision arose in a specific US employment and laboratory context. Its precise legal rules should not be transplanted into Indian law without examining the applicable legislation.

Case 5: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

United States Supreme Court · 569 U.S. 576

Issue: Whether naturally occurring human DNA could be patented merely because it had been isolated.

Decision: The US Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated, while synthetically created complementary DNA may qualify in circumstances described by the Court.

Relevance: The case helps distinguish between biological material, discoveries about human biology, and certain engineered inventions.

For commercial biosurveillance, it is relevant to the limits of proprietary claims involving genetic information and biotechnology. However, patent eligibility is not the same question as ownership of a biological sample, privacy rights, permission to conduct research, or entitlement to commercial profits.

Comparative summary

These cases establish relevant legal principles; they do not collectively constitute a single, formally recognized “Commercial Biosurveillance Accountability Doctrine.”

5. Core accountability principles

A workable accountability doctrine should determine which organization is responsible for each stage of the biosurveillance process.

A. Responsibility across the data lifecycle

Collection

Was the sample or measurement collected lawfully, with appropriate notice and authorization?

Storage and analysis

Are access controls, retention limits, and security measures appropriate?

Sharing and commercialization

Is each transfer, secondary use, and commercial disclosure legally permitted?

Audit, correction, and remedy

Can affected individuals seek redress, and can regulators establish what happened?

The principal accountability questions are:

Who determined the purpose? The organization deciding why data is collected or processed may have primary statutory responsibilities.

Who performed the processing? Laboratories, cloud providers, analytics vendors, and research partners may have contractual or independent legal obligations.

Who benefited commercially? Commercial benefit can be relevant to assessing conduct, but it does not alone establish liability.

Who caused the harm? Liability depends on the applicable cause of action, duty, breach, causation, and any relevant defenses.

A contract between two companies cannot necessarily eliminate statutory duties owed to individuals or prevent a regulator from exercising its powers.

B. Informed consent and secondary use

A patient may agree to genetic testing for diagnosis without agreeing to unrelated advertising or unrestricted commercial research.

A sound governance model should distinguish between:

Clinical diagnosis and treatment.

Quality assurance and laboratory operations.

Scientific research.

Commercial product development.

Sale or disclosure of identifiable data.

Continuous monitoring and predictive profiling.

Where consent is required, it should be informed, sufficiently specific, and obtained through a valid process. Other lawful bases or statutory exceptions may apply in some circumstances.

An organization should not assume that anonymization completely resolves every concern. Genetic information may sometimes be linked back to individuals or reveal information about biological relatives.

C. Discrimination and unfair profiling

Commercial biological monitoring can create risks if genetic or physiological information is used to determine:

Eligibility for employment.

Insurance eligibility or pricing.

Access to financial services.

Targeted marketing based on inferred medical vulnerability.

Access to particular services or benefits.

The legality of these practices depends on the applicable anti-discrimination, insurance, employment, consumer, and data-protection rules. Not every adverse decision based on health information is automatically unlawful, but a company must not assume that predictive accuracy makes the decision legally permissible.

6. Corporate governance framework

A company operating a biosurveillance system should adopt the following controls.

India's DPDP Rules, 2025, provide a statutory basis for several of these measures, including security safeguards, breach notification, and enhanced assessment and audit obligations for Significant Data Fiduciaries. The precise duties and commencement dates must be checked against the official Rules and their subsequent corrections.

MeitY+1

7. Liability for commercial biosurveillance violations

Depending on the facts and applicable law, several types of liability may arise.

Statutory and regulatory liability

Processing in breach of applicable data-protection requirements may result in regulatory directions, monetary penalties, or other statutory consequences.

Contractual liability

A provider may be liable for breach of confidentiality commitments, data-use restrictions, or other enforceable contractual terms.

Civil liability

Depending on the jurisdiction, unauthorized disclosure or negligent security may support claims involving breach of confidence, negligence, privacy-related torts, or other recognized causes of action.

Employment and discrimination liability

Unlawful testing or use of biological information in workplace decisions may trigger applicable employment, equality, privacy, or human-rights protections.

Corporate and managerial accountability

Corporate liability may arise where legal requirements are breached. Personal liability for directors or officers depends on the relevant statute, their conduct, and the applicable rules for attributing responsibility.

A data breach does not automatically establish every form of liability. Investigators and courts must examine the governing legal duty, the facts, the causal connection to harm where required, and available defenses.

8. Hypothetical case study

Facts: A commercial genetic-testing company collects saliva samples from 100,000 customers. Its privacy notice describes ancestry testing, but the company later transfers identifiable genetic information to an unrelated pharmaceutical marketing company without obtaining any additional authorization.

The recipient uses the information to infer health risks and target advertisements. Some customers discover that information about their biological relatives has also been inferred.

Legal analysis:

Purpose and consent: The original notice may not authorize the unrelated transfer and advertising use. Its adequacy must be assessed under the applicable law.

Privacy: The sensitive nature of genetic information strengthens the need for careful scrutiny, consistent with the privacy principles in Puttaswamy and the proportionality concerns in S. and Marper.

Secondary use: The company must establish the legal basis for the transfer and the recipient's processing.

Security and governance: Investigators should examine access logs, vendor agreements, data minimization, retention, and the company's internal approvals.

Remedies: Depending on the governing law and findings, affected people may have access to complaint mechanisms or other statutory, contractual, or civil remedies.

Conclusion: The fact that customers voluntarily provided saliva for testing does not automatically authorize every later use of their genetic information.

9. Critical legal issues and unresolved questions

Commercial biosurveillance raises several questions that existing legal systems do not always resolve uniformly.

Data versus physical samples: Legal rights in a biological specimen may differ from rights in the genetic information extracted from it.

Anonymization: Removing names does not guarantee that genetic datasets can never be re-identified.

Familial privacy: One person's genetic information can reveal information about relatives who never supplied a sample.

Consent fatigue: Long, complicated notices may fail to provide meaningful practical understanding.

Power imbalance: Employees, patients, and insurance applicants may have limited ability to refuse monitoring.

Cross-border processing: International transfers can involve multiple legal systems, contracts, and regulatory authorities.

Research exceptions: The conditions under which research or statistical processing receives special treatment vary by jurisdiction and statute.

These questions support stronger transparency, independent review, purpose-specific safeguards, and meaningful avenues for redress.

10. Conclusion

The Commercial Biosurveillance Accountability Doctrine and Governance is most accurately understood as a proposed synthesis of established legal principles rather than a freestanding doctrine with one definitive judicial test.

Its central proposition is that the commercial value of biological information does not, by itself, give an organization unlimited authority to collect, retain, infer from, transfer, or monetize that information.

In India, Puttaswamy provides the constitutional privacy foundation, while the DPDP Act, 2023, and the DPDP Rules, 2025, supply an important statutory framework for covered digital personal-data processing. Other applicable laws may govern confidentiality, consumer rights, employment practices, research, and biotechnology.

A defensible system of governance therefore requires lawful processing, appropriate notice and consent where required, proportionate collection, secure retention, responsible commercial use, independent oversight, and effective remedies.

Legal research note: This is a general comparative analysis, not an opinion on a particular dispute. For litigation or compliance work, verify the latest statutory commencement notifications, amendments, binding judgments, and jurisdiction-specific rules.